2019 年至 2023 年 COVID-19 的 RNA 疫苗全球研究：文献计量分析。

BACKGROUND: Since the global pandemic of COVID-19 has broken out, thousands of pieces of literature on COVID-19 RNA vaccines have been published in various journals. The overall measurement and analysis of RNA vaccines for COVID-19, with the help of sophisticated mathematical tools, could provide deep insights into global research performance and the collaborative architectural structure within the scientific community of COVID-19 mRNA vaccines. In this bibliometric analysis, we aim to determine the extent of the scientific output related to COVID-19 RNA vaccines between 2019 and 2023. METHODS: We applied the Bibliometrix R package for comprehensive science mapping analysis of extensive bibliographic metadata retrieved from the Web of Science Core Collection database. On January 11th, 2024, the Web of Science database was searched for COVID-19 RNA vaccine-related publications using predetermined search keywords with specific restrictions. Bradford's law was applied to evaluate the core journals in this field. The data was analyzed with various bibliometric indicators using the Bibliometrix R package. RESULTS: The final analysis included 2962 publications published between 2020 and 2023 while there is no related publication in 2019. The most productive year was 2022. The most relevant leading authors in terms of publications were Ugur Sahin and Pei-Yong, Shi, who had the highest total citations in this field. The core journals were Vaccines, Frontiers in Immunology, and Viruses-Basel. The most frequently used author's keywords were COVID-19, SARS-CoV-2, and vaccine. Recent COVID-19 RNA vaccine-related topics included mental health, COVID-19 vaccines in humans, people, and the pandemic. Harvard University was the top-ranked institution. The leading country in terms of publications, citations, corresponding author country, and international collaboration was the United States. The United States had the most robust collaboration with China. CONCLUSION: The research hotspots include COVID-19 vaccines and the pandemic in people. We identified international collaboration and research expenditure strongly associated with COVID-19 vaccine research productivity. Researchers' collaboration among developed countries should be extended to low-income countries to expand COVID-19 vaccine-related research and understanding.

背景：自 COVID-19 全球大流行爆发以来，各种期刊上发表了数千篇关于 COVID-19 RNA 疫苗的文献。借助复杂的数学工具，对 COVID-19 RNA 疫苗进行整体测量和分析，可以深入了解全球研究绩效以及 COVID-19 mRNA 疫苗科学界的协作架构结构。在这项文献计量分析中，我们旨在确定 2019 年至 2023 年间与 COVID-19 RNA 疫苗相关的科学产出的程度。

方法：我们应用 Bibliometrix R 包对从 Web of Science Core Collection 数据库中检索到的广泛文献元数据进行全面的科学图谱分析。2024 年 1 月 11 日，使用预定的搜索关键字和特定限制在 Web of Science 数据库中搜索与 COVID-19 RNA 疫苗相关的出版物。应用 Bradford 定律评估该领域的核心期刊。使用 Bibliometrix R 包，使用各种文献计量指标对数据进行分析。

结果：最终分析包括 2020 年至 2023 年期间发表的 2962 篇出版物，而 2019 年没有相关出版物。最具生产力的一年是 2022 年。就出版物而言，最相关的主要作者是 Ugur Sahin 和 Pei-Yong，Shi，他们在该领域的总引用量最高。核心期刊是《疫苗》、《免疫学前沿》和《病毒-Basel》。使用最频繁的作者关键词是 COVID-19、SARS-CoV-2 和疫苗。最近与 COVID-19 RNA 疫苗相关的主题包括心理健康、人类 COVID-19 疫苗、人和大流行。哈佛大学是排名最高的机构。就出版物、引文、通讯作者国家和国际合作而言，领先的国家是美国。美国与中国的合作最为紧密。

结论：研究热点包括 COVID-19 疫苗和人类大流行。我们确定了国际合作和研究支出与 COVID-19 疫苗研究生产力密切相关。发达国家研究人员之间的合作应该扩展到低收入国家，以扩大 COVID-19 疫苗相关的研究和理解。